TScan Therapeutics (TCRX) News Today $2.40 -0.06 (-2.44%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Barclays Sticks to Its Buy Rating for TScan Therapeutics (TCRX)January 16 at 11:15 PM | markets.businessinsider.comTScan Therapeutics' SWOT analysis: innovative t-cell therapy stock faces pivotal yearJanuary 16 at 11:15 PM | msn.comHead to Head Analysis: TScan Therapeutics (NASDAQ:TCRX) versus bluebird bio (NASDAQ:BLUE)January 12, 2025 | americanbankingnews.comTScan Shares Jump 23% on Securities Purchase AgreementDecember 26, 2024 | marketwatch.comTScan Therapeutics To Offer $30 Mln Pre-funded Warrants At 37% PremiumDecember 26, 2024 | markets.businessinsider.comTScan Therapeutics announces $30M registered direct offeringDecember 26, 2024 | markets.businessinsider.comTScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% PremiumDecember 26, 2024 | globenewswire.comWith 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backingDecember 25, 2024 | finance.yahoo.comWith 52% ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) boasts of strong institutional backingDecember 25, 2024 | finance.yahoo.comWedbush Reiterates "Outperform" Rating for TScan Therapeutics (NASDAQ:TCRX)Wedbush reissued an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research note on Monday.December 23, 2024 | marketbeat.comTScan Therapeutics refinances existing convertible debt facilityDecember 23, 2024 | markets.businessinsider.comTScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley BankDecember 23, 2024 | globenewswire.comWedbush Has Pessimistic Outlook of TCRX FY2026 EarningsTScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at Wedbush dropped their FY2026 earnings per share estimates for TScan Therapeutics in a research report issued to clients and investors on Tuesday, December 10th. Wedbush analyst D. Nierengarten now forecasts that the comDecember 13, 2024 | marketbeat.comTScan Therapeutics: Promising Phase I ALLOHA Trial Results and Future Pivotal Study Drive Buy RatingDecember 12, 2024 | markets.businessinsider.comTScan Therapeutics’ TSC-101: Strong Buy Rating on Promising Clinical and Market PotentialDecember 11, 2024 | markets.businessinsider.comPromising Potential for TScan Therapeutics: Buy Rating Affirmed on Strong Clinical Data and Strategic InitiativesDecember 11, 2024 | markets.businessinsider.comPromising Trial Results and Safety Profile Justify Buy Rating for TScan TherapeuticsDecember 11, 2024 | markets.businessinsider.comThe Analyst Landscape: 5 Takes On TScan TherapeuticsDecember 11, 2024 | benzinga.comTScan Therapeutics (NASDAQ:TCRX) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $11.00 target price on shares of TScan Therapeutics in a research note on Wednesday.December 11, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX)HC Wainwright restated a "buy" rating and issued a $15.00 target price on shares of TScan Therapeutics in a report on Wednesday.December 11, 2024 | marketbeat.comTScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and ExpositionDecember 9, 2024 | globenewswire.comMorgan Stanley Keeps Their Buy Rating on TScan Therapeutics (TCRX)December 6, 2024 | markets.businessinsider.comTScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive YearsDecember 5, 2024 | globenewswire.comTScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development StrategyDecember 2, 2024 | globenewswire.comLMR Partners LLP Trims Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX)LMR Partners LLP lessened its holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 89.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 71,800 shares of the company's stock after selling 593,729 shares during the quarter.November 21, 2024 | marketbeat.comTScan Therapeutics' SWOT analysis: biotech stock poised for key catalystsNovember 15, 2024 | investing.comPromising Clinical Outcomes and Market Potential Propel TScan Therapeutics to a Buy RatingNovember 15, 2024 | markets.businessinsider.comTScan Therapeutics' (TCRX) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Friday.November 15, 2024 | marketbeat.comEquities Analysts Set Expectations for TCRX FY2024 EarningsTScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities research analysts at Lifesci Capital reduced their FY2024 earnings per share (EPS) estimates for shares of TScan Therapeutics in a report issued on Tuesday, November 12th. Lifesci Capital analyst S. Slutsky now forecasts that the comNovember 15, 2024 | marketbeat.comEquities Analysts Offer Predictions for TCRX FY2024 EarningsTScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Stock analysts at Wedbush increased their FY2024 earnings per share estimates for shares of TScan Therapeutics in a report released on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($1.09)November 15, 2024 | marketbeat.comTScan Therapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comWedbush Increases Earnings Estimates for TScan TherapeuticsTScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Wedbush boosted their FY2028 EPS estimates for TScan Therapeutics in a report released on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of $0.46 for the year, up from theNovember 14, 2024 | marketbeat.comPositive Outlook for TScan Therapeutics: Promising Heme and Solid Tumor Program Developments Support Buy RatingNovember 13, 2024 | markets.businessinsider.comTScan Therapeutics: Buy Rating Backed by Strong Clinical Results and Strategic AdvancementsNovember 13, 2024 | markets.businessinsider.comTScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 12, 2024 | finance.yahoo.comPromising Phase I Results and Strong Safety Profile Reinforce Buy Rating for TScan TherapeuticsNovember 6, 2024 | markets.businessinsider.comBuy Rating for TScan Therapeutics Driven by Promising Phase 1 Trial Results for TCR-T Cell TherapiesNovember 6, 2024 | markets.businessinsider.comDemystifying TScan Therapeutics: Insights From 4 Analyst ReviewsNovember 6, 2024 | benzinga.comTScan Therapeutics' (TCRX) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $11.00 target price on shares of TScan Therapeutics in a research report on Wednesday.November 6, 2024 | marketbeat.comTScan Therapeutics announces preliminary results from ALLOHA Phase 1 trialNovember 5, 2024 | markets.businessinsider.comTScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and ExpositionNovember 5, 2024 | globenewswire.comTScan Therapeutics (TCRX) Gets a Buy from BarclaysOctober 30, 2024 | markets.businessinsider.comTCRX TScan Therapeutics, Inc.October 20, 2024 | seekingalpha.comBank of Montreal Can Invests $749,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX)Bank of Montreal Can acquired a new stake in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 120,454 shares of the company's stock, valued at approximately $749,000. Bank of Montreal Can owned 0.October 8, 2024 | marketbeat.comMarshall Wace LLP Boosts Holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX)Marshall Wace LLP increased its holdings in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) by 60.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 307,487 shares of the company's stock afteOctober 6, 2024 | marketbeat.comTScan Therapeutics (NASDAQ:TCRX) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comTScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual MeetingOctober 4, 2024 | globenewswire.comTScan Therapeutics, Inc. (NASDAQ:TCRX) Sees Significant Growth in Short InterestTScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 1,800,000 shares, an increase of 31.4% from the August 31st total of 1,370,000 shares. Approximately 4.3% of the company's stock are short sold. Based on an average daily volume of 360,200 shares, the days-to-cover ratio is presently 5.0 days.September 27, 2024 | marketbeat.comBarbara Klencke Acquires 5,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) StockSeptember 25, 2024 | insidertrades.com940,831 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Purchased by Great Point Partners LLCGreat Point Partners LLC purchased a new position in TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 940,831 shares of the company's stock, valued at approximSeptember 24, 2024 | marketbeat.com Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRX Media Mentions By Week TCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TCRX News Sentiment▼0.550.50▲Average Medical News Sentiment TCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TCRX Articles This Week▼32▲TCRX Articles Average Week Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VectivBio News Today Kura Oncology News Today Tectonic Therapeutic News Today CARGO Therapeutics News Today Humacyte News Today Annexon News Today Pharvaris News Today Keros Therapeutics News Today Mereo BioPharma Group News Today Rapport Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TCRX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
